alendronate has been researched along with Duodenal Diseases in 2 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Duodenal Diseases: Pathological conditions in the DUODENUM region of the small intestine (INTESTINE, SMALL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Isolated case reports of gastric ulcers after alendronate sodium use raised concern about the gastroduodenal safety of daily alendronate." | 3.71 | Gastric and duodenal safety of daily alendronate. ( Andrade, SE; Beck, A; Boles, M; Buist, DS; Carey, VJ; Chan, KA; Chandler, JM; Chase, GA; Donahue, JG; Ettinger, B; Fishman, P; Goodman, M; Guess, HA; Gurwitz, JH; LaCroix, AZ; Levin, TR; Platt, R, 2002) |
| "Alendronate use was not associated with a significant increase in upper GI tract events among women at increased risk for these events (those aged > or =75 years with previous upper GI tract disease or using nonsteroidal anti-inflammatory drugs)." | 2.69 | Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. ( Bauer, DC; Black, D; Ensrud, K; Freedholm, D; Hochberg, M; Musliner, T; Nevitt, M; Thompson, D, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, DC | 1 |
| Black, D | 1 |
| Ensrud, K | 1 |
| Thompson, D | 1 |
| Hochberg, M | 1 |
| Nevitt, M | 1 |
| Musliner, T | 1 |
| Freedholm, D | 1 |
| Donahue, JG | 1 |
| Chan, KA | 1 |
| Andrade, SE | 1 |
| Beck, A | 1 |
| Boles, M | 1 |
| Buist, DS | 1 |
| Carey, VJ | 1 |
| Chandler, JM | 1 |
| Chase, GA | 1 |
| Ettinger, B | 1 |
| Fishman, P | 1 |
| Goodman, M | 1 |
| Guess, HA | 1 |
| Gurwitz, JH | 1 |
| LaCroix, AZ | 1 |
| Levin, TR | 1 |
| Platt, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial[NCT00398931] | Phase 3 | 1,099 participants (Actual) | Interventional | 1998-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for alendronate and Duodenal Diseases
| Article | Year |
|---|---|
Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Digestive System; Double-Blind Method; Duodenal | 2000 |
1 other study available for alendronate and Duodenal Diseases
| Article | Year |
|---|---|
Gastric and duodenal safety of daily alendronate.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Cohort Studies; Duodenal Diseases; Duodenal Ulcer; Fema | 2002 |